1 minute to Read

The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Significant opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.

30 March 2022
10 minutes to Read + 2 minutes to Watch

Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.

An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box. 

He Ako Hiringa
15 November 2021
60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Dr Raewyn Fisher
24 August 2021

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2

Read the HAH Bulletin to find out more.

He Ako Hiringa
19 July 2021